Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: Report from a randomized, controlled trial

Stroke

Volumn 42, Issue 8, 2011, Pages 2229-2234

  Chen, Celia S ^a   Lee, Andrew W ^a   Campbell, Bruce ^b   Lee, Tien ^a   Paine, Mark ^b,c   Fraser, Clare ^d   Grigg, John ^d   Markus, Romesh ^e  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

Author keywords

ophthalmology; retinal ischemia; thrombolysis; thrombolytic agents; tPA

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; CENTRAL RETINA ARTERY OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RETINAL ARTERY OCCLUSION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79961207711     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.613653     Document Type: Article

References (27)

1. Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol. 1999;128:733-738. (Pubitemid 30001769)
2. Rumelt S, Brown GC. Update on treatment of retinal arterial occlusions. Curr Opin Ophthalmol. 2003;14:139-141. (Pubitemid 36801959)
3. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol. 2005;140:376-391.
4. Fraser Scott G, Adams W. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev. 2009.
5. Schumacher M, Schmidt D, Jurklies B, Gall C, Wanke I, Schmoor C, Maier-Lenz H, Solymosi L, Brueckmann H, Neubauer AS, Wolf A, Feltgen N. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology. 2010;117:1367-1375.
6. Schmidt DP, Schulte-Monting J, Schumacher M. Prognosis of central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment. AJNR Am J Neuroradiol. 2002;23:1301-1307. (Pubitemid 35033877)
7. Atebara NH, Carter GC, Cater J. Efficacy of anterior chamber paracentesis and carbogen in treating acute nonarteric central retinal artery occlusion. Ophthalmology. 1995;102:2029-2035. (Pubitemid 26004464)
8. Augsburger JJ, Magargal LE. Visual prognosis following treatment of acute central retinal artery occlusion. Br J Ophthalmol. 1980;64:913-917. (Pubitemid 11217300)
9. del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr, on behalf of the American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009:40:2945-2948.
10. Arnold M, Koerner U, Remonda L, Nedeltchev K, Mattle HP, Schroth G, Sturzenegger M, Weber J, Koerner F. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatry. 2005;76: 196-199. (Pubitemid 40143707)
11. Beatty S, Au-Eong KG. Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data. Br J Ophthalmol. 2000;84:914-916. (Pubitemid 30599103)
12. Biousse V, Calvetti O, Bruce BB, Newman NJ. Thrombolysis for central retinal artery occlusion. J Neuroophthalmol. 2007;21:215-230. (Pubitemid 47482594)
13. Chen CS, Lee AW, Campbell B, Paine M, Lee T, Fraser C, Grigg J, Markus R, Williams K, Coster DJ. Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion. Int J Stroke. 2011;6:87-89.
14. Hayreh SS, Kolder HE, Weingeist TA. Central retinal artery occlusion and retinal tolerance time. Ophthalmology. 1980;87:75-78. (Pubitemid 10196118)
15. Richard G, Lerche RC, Knospe V, Zeumer H. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology. 1999;106:768-773. (Pubitemid 30194321)
16. Kattah JC, Wang DZ, Reddy C. Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion. Arch Ophthalmol. 2002;120:1234-1236. (Pubitemid 35034356)
17. Feltgen N, Neubauer A, Jurklies B, Schmoor C, Schmidt D, Wanke J, Maier-Lenz H, Schumacher M. Mutlicenter study of the European assessment group for lysis in the eye (EAGLE) for the treatment of central retinal artery occlusio: design issues and implications. EAGLE study report no. 1. Graefes Arch Clin Exp Ophthalmol. 2006;244: 950-956. (Pubitemid 44184499)
18. The GISSI Study Group. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
19. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24:1-10. (Pubitemid 47026135)
20. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008;79:1093-1099.
21. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in strokemonitoring study (SITS-MOST): an observational study. Lancet. 2007; 369:275-282. (Pubitemid 46138121)
22. Aldrich EM, Lee AW, Chen CS, Gottesman RF, Bahouth MN, Gailloud P, Murphy K, Wityk R, Miller NR. Local intra-arterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience. Stroke. 2008;39:1746-1750.
23. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: the American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276-2293.
24. Saver JL. Proposal for a universal definition of cerebral infarction. Stroke. 2008;39:3110-3115.
25. The ATLANTIS, ECASS, and NINDS-rtPA study group investigators. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363: 768-774.
26. Hattenbach LO, Kuhli-Hattenbach C, Scharrer I, Baatz H. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. Am J Ophthalmol. 2008;146:700-706.
27. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost. 2008;100:184-195.